within Pharmacolibrary.Drugs.ATC.R;

model R01AA05
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 0.05 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R01AA05</td></tr><td>route:</td><td>intranasal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Oxymetazoline is an imidazoline decongestant, primarily used as a topical nasal spray for temporary relief of nasal congestion due to common cold, hay fever, or allergies. It acts as an alpha-adrenergic agonist leading to vasoconstriction. Oxymetazoline is available in over-the-counter formulations and is still approved for use today.</p><h4>Pharmacokinetics</h4><p>There are very limited published data on the pharmacokinetic parameters of oxymetazoline in humans, especially after intranasal administration. No full pharmacokinetic profile with explicit parameters based on published population PK models is available in the literature.</p><h4>References</h4><ol><li><p>Giannakopoulos, H, et al., &amp; Hersh, EV (2012). The cardiovascular effects and pharmacokinetics of intranasal tetracaine plus oxymetazoline: preliminary findings. <i>Journal of the American Dental Association (1939)</i> 143(8) 872–880. DOI:<a href=&quot;https://doi.org/10.14219/jada.archive.2012.0291&quot;>10.14219/jada.archive.2012.0291</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22855901/&quot;>https://pubmed.ncbi.nlm.nih.gov/22855901</a></p></li><li><p>Cacek, AT, et al., &amp; Gopalakrishnan, M (2017). Population Pharmacokinetics of an Intranasally Administered Combination of Oxymetazoline and Tetracaine in Healthy Volunteers. <i>Journal of clinical pharmacology</i> 57(2) 247–254. DOI:<a href=&quot;https://doi.org/10.1002/jcph.799&quot;>10.1002/jcph.799</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27436060/&quot;>https://pubmed.ncbi.nlm.nih.gov/27436060</a></p></li><li><p>Hersh, EV, et al., &amp; Moore, PA (2016). Intranasal tetracaine and oxymetazoline: a newly approved drug formulation that provides maxillary dental anesthesia without needles. <i>Current medical research and opinion</i> 32(11) 1919–1925. DOI:<a href=&quot;https://doi.org/10.1080/03007995.2016.1238352&quot;>10.1080/03007995.2016.1238352</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27646144/&quot;>https://pubmed.ncbi.nlm.nih.gov/27646144</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R01AA05;
